Crinetics Pharmaceuticals (CRNX) Other financing activities (2017 - 2026)

Crinetics Pharmaceuticals' Other financing activities history runs 10 years deep, the most recent figure standing at $9.9 million for Q1 2026.

• On a quarterly basis, Other financing activities rose 124.0% year-over-year to $9.9 million in Q1 2026; TTM through Mar 2026 was $9.9 million, a 163.19% increase from a year earlier, with the FY2023 full-year figure at $26000.0, down 99.45% from the prior year.
• Other financing activities climbed to $9.9 million in Q1 2026 per CRNX's latest filing, from -$14.6 million in the prior quarter.
• Across five years, Other financing activities topped out at $11.7 million in Q3 2025 and bottomed at -$32.9 million in Q4 2024.
• The 5-year median for Other financing activities is $2.0 million (2024), against an average of -$20866.7.
• Biggest YoY gain for Other financing activities was 3022.81% in 2022; the steepest drop was 822.18% in 2022.
• Year by year, Other financing activities stood at $4.7 million in 2022, then slumped by 327.2% to -$10.7 million in 2023, then tumbled by 206.5% to -$32.9 million in 2024, then surged by 55.66% to -$14.6 million in 2025, then soared by 168.19% to $9.9 million in 2026.
• Per Business Quant, the three latest CRNX Other financing activities figures stand at $9.9 million (Q1 2026), -$14.6 million (Q4 2025), and $11.7 million (Q3 2025).